The Technical Analyst
PharmaCyte Biotech, Inc. [PMCB]
Exchange: PNK Industry: Biotechnology
PharmaCyte Biotech, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.65% $2.11
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.86 mill |
| EPS: | -1.480 |
| P/E: | -1.430 |
| Earnings Date: | Mar 14, 2024 |
| SharesOutstanding: | 8.46 mill |
| Avg Daily Volume: | 0.0257 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.430 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.430 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.49 (65.46%) $1.381 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.971 - 2.25 ( +/- 6.59%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-20 | Weinstein Robert | Buy | 61 248 | Stock Option (Right to Buy) |
| 2023-11-20 | Walker Wayne Remell | Buy | 61 248 | Stock Option (Right to Buy) |
| 2023-11-20 | Trujillo Carlos | Buy | 85 000 | Stock Option (Right to Buy) |
| 2023-11-20 | Silverman Joshua | Buy | 170 000 | Stock Option (Right to Buy) |
| 2023-11-20 | Schechter Jonathan | Buy | 61 248 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 57.20 |
| Last 54 transactions |
| Buy: 749 992 | Sell: 831 346 |
Forecast:
16:00 - $2.18
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.18
Forecast 2: 16:00 - $2.18
Forecast 3: 16:00 - $2.18
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.11 (-3.65% ) |
| Volume | 0.0034 mill |
| Avg. Vol. | 0.0257 mill |
| % of Avg. Vol | 13.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PMCB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PMCB
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Latest Press Releases
2023-11-15 08:30:00 - Press Release
Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women's Health Innovator Femasys, Inc.
Las vegas--(business wire)--pharmacyte biotech, inc. (nasdaq: pmcb) (“pharmacyte” or the “company”) announces it has made a $5 million investment in femasys, inc. (nasdaq:femy) (“femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. this is the company's first investment in externally deve.
2023-10-31 09:15:00 - Press Release
Pharmacyte Biotech Provides Corporate Update On Cell-in-a-box Technology
Las vegas--(business wire)--pharmacyte biotech, inc. (nasdaq: pmcb) (“pharmacyte” or the “company”) provides an update on its investigation of its cell-in-a-box technology and initial next steps in development. following a comprehensive scientific review of amassed data, the company is in the process of requesting a meeting with the u.s. food and drug administration (fda) for guidance on further development of the technology. the meeting is expected to occur during the first quarter of 2024. in.
2023-06-15 09:15:00 - Press Release
Pharmacyte Biotech Announces Final Results Of Tender Offer
Las vegas--(business wire)--pharmacyte biotech, inc. (nasdaq: pmcb) (“pharmacyte” or the “company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the company's common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. the tender offer expired one minute after 11:59 p.m. on june 9, 2023, and was funded entirely through the company's cash on.
2023-05-11 08:30:00 - Press Release
Pharmacyte Biotech Announces Cash Tender Offer For Up To 7,750,000 Shares At $3.25 Per Share
Las vegas--(business wire)--pharmacyte biotech, inc. (nasdaq: pmcb) (“pharmacyte” or the “company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. the company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertib.
2023-02-02 09:00:00 - Press Release
Pharmacyte Biotech To Implement Second $10-million Share Repurchase Plan
Las vegas--( business wire )--pharmacyte biotech, inc. (nasdaq:pmcb) (“pharmacyte” or the “company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, cell-in-a-box ® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its board of directors has authorized a second share repurchase program to repurchase up to $10 million of pharmacyte's outstanding common stock. this second share repurchase authorization is effective immediately for a two-year period. pharmacyte expects to fund the program with its available cash. the company enacted a similar program in june 2022.
Latest News
2022-01-07 02:59:08 - Seeking Alpha
Is This A Good Time To Invest In PharmaCyte?
2021-10-18 06:00:30 - InvestorPlace
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.
2021-09-09 12:43:50 - InvestorPlace
7 Penny Stocks Waiting on The FDA for Rocket Fuel
News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.
2021-09-09 11:00:54 - Pulse2
PMCB Stock: Why It Is Trading Higher Today
The stock price of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is trading at over 20% pre-market today. This is why it happened.
2021-09-09 10:03:50 - InvestorPlace
After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble
There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.
2021-08-23 16:39:00 - Business Wire
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte closes $70 million offering and explains how these funds will be used to grow the Company into the future and create shareholder value.
2021-08-21 02:08:50 - Seeking Alpha
PharmaCyte Biotech: Buy The 'Dump'
2021-08-19 06:05:38 - Pulse2
PharmaCyte Biotech Shares Increased 189.47%: Details
The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by 189.47% yesterday. These are some details you should know.
2021-08-18 10:25:20 - InvestorPlace
PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket
PharmaCyte Biotech (PMCB) stock is taking off Wednesday and there are a few things that potential investors need to know about the company. The post PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket appeared first on InvestorPlace.
2021-08-18 07:25:30 - Pulse2
PharmaCyte Biotech Shares Increase Over 20% Pre-Market: Why It Happened
The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by over 20% pre-market. This is why it happened.